- NEWS AND VIEWS
Immune-cell crosstalk in multiple sclerosis
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 563, 194-195 (2018)
doi: https://doi.org/10.1038/d41586-018-07063-z
References
Wekerle, H. Acta Neurol. Scand. 136 (Suppl. 201), 22–25 (2017).
Jelcic, I. et al. Cell 175, 85–100 (2018).
Mohme, M. et al. Brain 136, 1783–1798 (2013).
Oksenberg, J. R., Baranzini, S. E., Sawcer, S. & Hauser, S. L. Nature Rev. Genet. 9, 516–526 (2008).
Panitch, H. S., Hirsch, R. L., Haley, A. S. & Johnson, K. P. Lancet 329, 893–895 (1987).
Bitsch, A., Schuchardt, J., Bunkowski, S., Kuhlmann, T. & Bruck, W. Brain 123, 1174–1183 (2000).
Bruck, W. et al. Immunobiology 195, 588–600 (1996).
Hendriks, R. W., Yuvaraj, S. & Kil, L. P. Nature Rev. Cancer 14, 219–232 (2014).
Mertin, J. Proc. R. Soc. Med. 70, 871–874 (1977).
Greenfield, A. L. & Hauser, S. L. Annls Neurol. 83, 13–26 (2018).
Hauser, S. L. et al. N. Engl. J. Med. 358, 676–688 (2008).
Wekerle, H. Autoimmunity 50, 57–60 (2017).
Kivisäkk, P. et al. Clin. Exp. Immunol. 129, 510–518 (2002).
Restorick, S. M. et al. Brain Behav. Immun. 64, 71–79 (2017).
Richert, J. R., McFarlin, D. E., Rose, J. W., McFarland, H. F., Greenstein, J. I. J. Neuroimmunol. 5, 317–324 (1983).
Competing Interests
R. M. R. was employed by Biogen, the manufacturer of natalizumab, from October 2014 to November 2017. He retains a small equity interest in Biogen.